Intec Pharma (NTEC) Earns News Sentiment Rating of 0.26

Press coverage about Intec Pharma (NASDAQ:NTEC) has trended positive on Tuesday, Accern reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Intec Pharma earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the company’s share price in the next several days.

A number of equities analysts recently issued reports on NTEC shares. Zacks Investment Research downgraded shares of Intec Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 24th. ValuEngine downgraded shares of Intec Pharma from a “hold” rating to a “sell” rating in a report on Friday, June 9th. Finally, Maxim Group set a $9.00 price target on shares of Intec Pharma and gave the company a “buy” rating in a report on Wednesday, May 24th.

Intec Pharma (NASDAQ:NTEC) traded up 0.88% during trading on Tuesday, hitting $5.70. 204 shares of the stock traded hands. The stock’s market cap is $78.30 million. Intec Pharma has a 52-week low of $4.20 and a 52-week high of $6.36. The stock has a 50 day moving average price of $5.48 and a 200-day moving average price of $5.23.

ILLEGAL ACTIVITY WARNING: This news story was originally published by BNB Daily and is owned by of BNB Daily. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.baseball-news-blog.com/2017/07/25/intec-pharma-ntec-earning-positive-press-coverage-accern-reports-updated-updated.html.

About Intec Pharma

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Insider Buying and Selling by Quarter for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply